Connect with us

Opinion

Trends and expectations for the fertility sector in 2023

By Eran Eshed, CEO and co-founder of Fairtility

Published

on

Eran Eshed

2022 featured some pivotal moments whose impacts will reverberate into the new year. Eran Eshed, CEO and co-founder of Fairtility, reflects on the developments poised to shape fertility care in 2023.

This year, we saw the US Supreme Court overturn Roe v Wade in a decision with passionate responses from both sides of the political aisle. Through 2022, we have started to learn to live alongside Covid.

From a technological perspective, AI has clearly entered the Zeitgeist with endless social media posts featuring AI-generated art and text, stoking both excitement and fear of how AI will impact our future lives. And, we are facing a global economic downturn that is impacting people around the world with spiking rates of inflation and rising cost of living globally.

With these new realities in play, the field of fertility care will feel the effects of all of these trends in different, but significant ways. Let’s take a look at how some of 2022’s pivotal developments are poised to shape fertility care in 2023.

Roe v Wade and IVF Clinics in 2023

The overturning of Roe v Wade by the US Supreme may have a significant impact on IVF in 2023, specifically in states that do not explicitly allow for IVF or IVF embryo selection as part of their anti-abortion laws.

With state-by-state laws forming in the coming year, prospective parents will need to remain informed of their local legislation, as reproductive medical procedures may be restricted or entirely banned in certain states.

Consequently, prospective parents may need to travel out of state to receive IVF treatment. IVF clinics will have an uncertain year ahead as patient demand remains unpredictable in the wake of Roe v Wade.

Additionally, clinical IVF teams will need to remain vigilant as “foetal personhood” legislation, which suggests that foetuses and embryos have the same legal standing as a born child, may expose routine assisted reproductive technology procedures such as IVF to risk, and potential liability for providers.

IVF in the post-pandemic world requires innovation

We are seeing the impact today of healthcare treatment delays that occurred as a result of Covid. For prospective parents who are up against a biological clock, fertility treatment delays were agonizing. During the pandemic, many IVF clinics had to temporarily close the doors to patients.

As the world resettles into new routines alongside peeks and dips of Covid cases, patient demand for IVF is higher than ever.

However, filling this need is not simple as we face a global shortage of embryologists. Meeting this need requires the advancement of IVF technology to automate routine processes for clinicians, freeing up their time to service additional patients.

Digital transformation in this field will gain further momentum in 2023, as the introduction of new technologies into IVF clinics, such as AI-guided decision support tools, will help increase capacity, reduce costs, and improve access to reproductive health treatments.

The new generation of fertility patients are tech savvy

AI has entered our daily lives. This couldn’t be clearer as our social feeds are filled with ChatGPT and AI-generated portraits.

These new technological opportunities, combined with a younger generation that has grown up with endless access to information means today’s fertility patients are looking for greater automation, transparency and explainability in their care journey. This tech savvy generation wants to feel engaged and in control of their journey and choices.

Opportunity comes up against reality when prospective patients are sitting with their fertility specialists. The worst thing for prospective parents undergoing IVF to hear – other than the simple fact of an embryo transfer not implanting – is that there is no explanation for the failed attempt.

This can make patients feel they are sitting in the back seat of their treatments rather than in the driver’s seat.

Herein lies the opening where new AI solutions will have an impact. Digital technologies such as transparent AI tools, electronic witnessing and automated cryo storage are becoming more commonplace and widely deployed in the reproductive health space. These can enable greater transparency and increased clinician-patient collaboration.

Harnessing the power of AI to augment IVF decisions

AI is going to impact more than just the patient experience. Fertility care is moving toward new areas of sophistication, which is being driven by data.

New tools and technologies in health in general and IVF specifically enable collection of vast amounts of data that either could not be collected before or was not good enough quality.

New transparent AI tools can take advantage of this data, with the ability to manage, interpret and truly make sense of it all. This is enabling standardisation of clinical protocols and improving accuracy and consistency in clinical decision making, regardless of the experience level of the embryologist.

The image-based nature of IVF has made it ripe for AI transformation. Collecting vast amounts of aggregated data, and training AI algorithms to identify specific biomarkers as an embryo develops, is giving embryologists a new level of insights into the quality of developing embryos that is not possible with human analysis alone.

With millions of data points collected and analysed during an IVF cycle, embryologists are being armed with rich AI-driven biological data and quality assessments to help them determine the most viable embryos.

AI-powered embryo quality selection tools are being deployed into clinics around the world. Utilising these tools to support clinical decisions along the IVF treatment journey, we may expect to see an overall improvement of IVF care outcomes, with patients requiring fewer IVF rounds to achieve a live birth.

The pandemic economy – what’s in store for IVF?

One of the biggest challenges the world is grappling with as we close 2022 is the post-pandemic economic crisis. However, it is unlikely the economic downturn will affect the fertility care market in the way it has other fields.

Since peoples’ desire to become parents is a fundamental need for many, prospective parents will prioritise IVF over anything else. These single-minded patients will be doing their homework on which fertility care provider is most likely to help them fulfil their dreams.

Fertility clinics will need to up their offerings to prove to their potential patients that they can get the job done. This is going to position clinics utilising advancing AI decision support tools ahead of the rest, since prospective parents who are tight on funds will want to make sure they are given the best chance of success.

Advancements in technology can provide hope to those who are invested in the IVF process. It will facilitate a lot of the changes that we need to see, including improved access, lower costs, improved patient experiences and more consistent and objective clinical decision making.

Based on patient demand, IVF professional need, and the new technologies entering the IVF lab, 2023 is poised to be a year in which we see the bar raised on the standard of care in this field.

For more info, visit fairtility.com.

Opinion

How the UK’s ‘pharmacy first’ policy will change women’s healthcare

By Katherine Bridges, head of brand and clinical lead at the pharmacy app Charac

Published

on

On the January 31, the UK government will roll out its long-awaited “pharmacy first” policy, a measure designed to cut the size of the NHS backlog – which currently stands at around 7.6 million patients.

With “pharmacy first”, patients suffering from various lesser ailments – such as sore throats and shingles – will be directed to their local pharmacy as their first port of call.

Pharmacies will also be able to supply certain prescription medicines. It is hoped that this will ease pressure on Britain’s seriously overstretched hospitals and GPs.

The policy is set to transform healthcare provision in the UK, which is important for women’s health across the country. If the policy can be carried through successfully, women’s access to NHS will improve in a number of ways. The success of “pharmacy first” will, however, rely on a big technological upgrade to Britain’s 11,500 high-street pharmacies.

Improving women’s access

This shift of several key medical functions to Britain’s pharmacies will give women easier access to important medicines and treatments. For instance, under “pharmacy first” patients will be able to pick up prescription medicine for urinary tract infections (UTIs) from pharmacies; previously this required a GP appointment beforehand.

This change will be especially valuable for women, given that this ailment disproportionately affects women, with roughly 50 per cent experiencing one over the course of their lives.

Crucially, under the new policy, women will also be able to purchase contraceptive pills at their pharmacies without seeing a GP. It is vitally important, but easily prescribed and administered medications such as this that will see “pharmacy first” freeing up countless of hours of GP and hospital time.

Further, the reduction of pressure on GPs and hospitals will improve women’s access to critical medical procedures and treatments. For instance, the policy will put a dent in the NHS’s mastectomies backlog, which is currently putting thousands of women in the UK at a greater risk of breast cancer.

Femtech critical to making a success of “pharmacy first”

Of course, “pharmacy first” represents a very large administrative and operational task for Britain’s high-street pharmacies.

It is uncertain whether these pharmacies, in their current state, will be able to meet the challenge. Community pharmacies are often small and family run. As such, they find it difficult to afford key labour-saving technologies that cut costs and free up time.

These pharmacies’ internal systems are often ramshackle and antiquated. Many still run on paper, making everything from prescriptions to payroll arduous and time-consuming.

It is clear that these pharmacies will need to undergo a big technological upgrade as the policy is rolled out this year. Femtech will play a key role in this effort.

Femtech technologies could help pharmacists manage the transition to a greater scope of provision. For instance, femtech companies, such as Vivoo’s at-home women’s UTI test, could help pharmacists manage the task of treating this common women’s ailment.

Another would be the online self-assessment system Tuune, which matches women to the contraceptive treatment appropriate to their particular hormonal profile.

Innovations like these will be an essential part of women’s healthcare in the age of “pharmacy first”, driving efficiencies in high-street pharmacies and expanding women’s access to treatment.

The future of health tech will empower women

Other health technologies will help amplify the impact of femtech. Apps, such as Charac, offer a dashboard for both pharmacists and their customers, allowing customers to book pharmacy appointments and get their prescriptions delivered to their door.

These kinds of accessible, integrated health tech systems that will prove so valuable in the age of “pharmacy first” will also help improve patient outcomes for women. One of the primary hindrances to better healthcare for women is a lack of information and access.

Research by the Department of Health and Social Care revealed that around 85 per cent of British women did not feel comfortable talking to their GPs about their physical health, and a similar percentage can remember an occasion where they did not feel listened to by medical professionals.

Similarly, knowledge of women’s health issues is often low: less than one in five UK women felt that they had enough information on menstrual health, and less than one in 10 felt they knew enough about gynaecological conditions.

What’s clear is that a lack of information and access is leading to worse health outcomes for women than men, but health tech can make a valuable contribution – streamlining appointments and prescriptions, raising public awareness of health conditions and the treatment services that women can access and making patient outcomes and healthcare more equal.

As “pharmacy first” becomes policy, we have a chance to use the latest developments in femtech and health tech to both make a dent in the NHS backlog, and to put women’s healthcare on a surer foundation.

Katherine Bridges is head of brand and clinical lead at the pharmacy app Charac.

Continue Reading

Opinion

Transforming women’s health: a bold roadmap to a more equitable future

By Kavelle Christie, director of the gender equity and health justice program at Community Catalyst

Published

on

Equity lies at the heart of progress, demanding a healthcare system that not only provides affordability and accessibility but also centres the distinctive needs of women.

The deliberate inequities affecting Black, Indigenous, and Latinx women, transgender women, those in rural communities, women with disabilities and those with low incomes underscore the urgent need for transformative change.

From alarming maternal mortality rates among Black and Indigenous women to abortion bans, limited healthcare access in rural areas, discriminatory practices against women with disabilities and stigmatisation faced by Black, immigrant, and transgender women, these inequities demand a comprehensive reimagining of our healthcare system.

A robust, truly transformative healthcare system is the cornerstone of a thriving society and it is time for the nation to prioritise women’s health.

Expanding Medicaid in the ten remaining states and extending postpartum coverage to 12 months in every state are crucial steps in dismantling barriers that impede women’s health.

Additionally, improving Black maternal health outcomes and the preservation and enhancement of reproductive rights, which encompasses unfettered access to abortion care, comprehensive family planning services and contraceptives, form other vital pillars.

Improving Black maternal health outcomes

Maternal health remains a significant concern, particularly among Black women. Passing the federal Black Maternal Health Momnibus, introduced by Rep. Underwood and Sen. Booker, can help address inequities and promote access to quality maternal care.

In addition to passing the Momnibus, it’s time for the US to invest in an ethical supply chain to ensure the improvement of necessary pre- and postpartum drug delivery. By guaranteeing the consistent availability of essential medications, we can enhance the overall quality of care.

Power and control over women’s bodies

Every woman should have the autonomy to make informed decisions about her body and reproductive health.

Policies that fail to centre marginalised communities perpetuate existing power imbalances and exacerbate health disparities. Not only is it time to pass the federal Women’s Health Protection Act to re-establish a national right to abortion to create a just healthcare system for women, but it is likewise vital to implement policies that monitor and account for the funding and actions of crisis pregnancy centres  and anti-abortion maternity homes.

These often-unregulated places disseminate misleading information about abortion care, manipulate women and can come with deeply conservative ideologies, such as mandatory church service attendance in exchange for shelter and additional restrictions on reproductive choice.

Building a better healthcare system means we closely monitor and regulate crisis pregnancy centres and maternity homes, ensuring they provide comprehensive, unbiased, and evidence-based information and care to women without imposing ideological beliefs.

It is also essential to note that anti-abortionists are swiftly rolling out policies that would even prevent women from travelling on highways to access abortion services.

These predatory webs of restrictions to deprive us of our freedom are not merely about abortion rights; this is about who has power over you, who has the authority to make decisions for you and who is going to control how your future is going to be.

Therefore, to build a better healthcare system for women, we must fiercely defend abortion rights and dismantle any barriers that may obstruct women’s ability to make choices about their bodies and reproductive health.

We must give women back the power to control their own bodies, especially for those most impacted who have the least resources, who can’t afford to lose a job, who don’t have access to childcare, who have no access to healthcare and who face many more systemic barriers.

Transparency in healthcare decision-making processes is also vital. This extends to hospital ethics committees, which often make critical decisions about abortion access, but whose membership is often shrouded in secrecy.

For a more just healthcare system, we must eradicate this wall of secrecy and ensure transparency in these committees’ composition and decision-making process.

Women deserve to know that their healthcare decisions are made with impartiality and respect for their rights.

Protecting gender-affirming care

Gender-affirming care for transwomen is a critical component of comprehensive healthcare.

This specialised care involves a range of medical, psychological, and social interventions to align an individual’s physical characteristics with their gender identity. Key elements may include hormone therapy, gender confirmation surgery, mental health support, and ongoing medical monitoring.

Gender-affirming care is not only a matter of medical necessity for transwomen but is also closely tied to mental health, overall wellbeing, and a sense of self.

Creating a healthcare environment that offers inclusive, affordable, and accessible services for transwomen is essential to a holistic approach that acknowledges and validates their gender identity, ultimately contributing to better health outcomes and improved quality of life.

Kavelle Christie is the director of the gender equity and health justice program at Community Catalyst, a national health advocacy organisation that works alongside organisational partners across 45 states and territories to build people power and create a health system rooted in race equity and health justice.

Continue Reading

Opinion

The impact of menopause and ageing on urinary incontinence in women

By Lydia Zeller, CEO at Pelvital USA

Published

on

Lydia Zeller, CEO at Pelvital USA

The natural processes of menopause and ageing are not the biggest challenge women face when it comes to incontinence. The biggest challenges are the historic silence and assumption that our only options are pads or surgery.

One of the most rewarding aspects of my role as CEO of Pelvital is amplifying the conversation around women’s health, especially on historically stigmatised topics like urinary incontinence (UI) and menopause.

If you suffer from bladder leaks, you’re not alone. Research from 2022 shows more than 60 per cent of US women suffer some form of bladder leaks. It is unacceptable that an issue impacting over half of women has historically been kept quiet and stigmatised.

Women are led to believe that bladder leaks are a natural part of being a mum or growing older. That is not true. Although bladder leaks are common, they are not normal, and women should not accept them as such.

Fortunately, there are effective options for treating leaks and education is the first step in self-advocacy – one of the reasons why I love talking about this topic.

First, let’s talk about the different types of UI. Stress urinary incontinence presents as accidental leakage associated with activities like sneezing, laughing, coughing, or jumping.

Urge incontinence (including overactive bladder) involves the sudden urge to urinate followed by involuntary loss of urine. Mixed incontinence is the combination of stress and urge incontinence. Stress urinary incontinence (SUI) is the most common form and is often caused by weakened pelvic floor muscles.

While one in three mothers report SUI within three months of childbirth, UI prevalence indisputably increases with age: 62 per cent of women in their 40s have UI compared to 68 per cent of women in their 50’s, 72 per cent in their 60s and 83 per cent in their 70s.

But does menopause cause incontinence? Yes and no.

Menopause is defined as the natural event of a woman’s final menstrual cycle. It is associated with reduced functioning of the ovaries due to ageing, resulting in lower levels of oestrogen, progesterone, and testosterone.

While these steep hormonal drops don’t directly cause incontinence, they cause thinning of the tissues in the pelvic floor muscles during perimenopause (the time around menopause when your ovaries gradually stop working).

Combine this thinning with common unresolved pelvic floor weakness or injury (e.g. caused by pregnancy, childbirth, pelvic surgery, falls) and/or with common changes associated with ageing (e.g. lowered fluid intake, lowered activity, constipation) – and urinary incontinence can result.

Stress urinary incontinence is most often caused by weak pelvic floor muscles – and menopause-related changes exacerbate that weakness.

Pelvital on-staff pelvic health doctors of physical therapy Shravya Kovela and Leah Fulker describe how this works in a blog on the menopause / incontinence connection: Weak pelvic floor muscles are unable to contract properly to close the urethral sphincter where urine escapes the body.

When paired with hormonal changes of menopause and the resulting changes in tissue flexibility or elasticity of the vulva, vagina, and urethral sphincter, urinary incontinence will appear or worsen.

Furthermore, discomfort in the vulva and vagina associated with menopause-related vaginal dryness or pain may lead pelvic floor muscles to compensate, worsening urinary incontinence.

Interestingly, menopause and ageing do not equally impact incontinence. Menopause transition has been found to correlate with stress urinary incontinence, whereas increasing age and risk factors such as anxiety, BMI, and new onset diabetes correlate with both stress and urge incontinence. And new onset of SUI is highest in perimenopause as opposed to postmenopause.

But the natural processes of menopause and ageing are not the biggest challenge women face when it comes to incontinence. The biggest challenges are the historic silence and assumption that our only options are pads or surgery.

Tragically, according to the Study of Women’s Health Across the Nation (SWAN) – a historic study to define menopause transition and “characterise its biological and psychosocial antecedents and sequelae in an ethnically and racially diverse sample of midlife women” – fewer than 40 per cent of incontinent women even seek treatment from their healthcare provider.

Women are uncomfortable bringing this topic up with their providers and when they do, too often are dismissed without options.

Menopause gaslighting is occurring to women because historically there has been a significant lack of clinically proven conservative options for women who do not wish to have surgery.

Pelvic floor physical therapy has been the shining light here, but a mere one per cent of physical therapists specialise in the pelvic floor, resulting in significant access gaps.

The continued uptick in virtual pelvic health physical therapy options is a big positive, increasing access and enabling women to fit treatment into their lives. Similarly, evidence-based in-home treatment options allow women flexibility and clinicians the ability to extend their clinic walls and deliver conservative care at scale, with outcomes very similar to surgery.

This conversation is incomplete without mention of economics and gender equity. Not only has research into women’s health been historically massively underfunded, but women bear disproportionate out-of-pocket costs.

Specific to UI, 70 per cent of costs are borne by the woman. And that is also completely unacceptable. I am proud to be part of the growing cohort of femtech companies creating change and step by step moving towards broad access and insurance coverage. Women deserve no less.

Lydia Zeller is CEO at Pelvital USA, Inc., a Minnesota based femtech company providing products to restore pelvic floor health. Flyte by Pevital is an FDA-cleared novel in-home treatment for female urinary incontinence.

Continue Reading

Trending Posts

Receive updates from Femtech World

Sign up for updates from Femtech World

Trending

Copyright © 2023 Aspect Publishing Ltd. All Rights Reserved.